8-K
filed November 17, 2022, 6:59 PM ET
ticker IKT
CIK 0001750149
earnings
confidence high
sentiment negative
materiality 0.80
Inhibikase Q3 net loss $4.49M; FDA clinical hold on IkT-148009 programs
Inhibikase Therapeutics, Inc.
2022-Q3 EPS reported
-$0.55
revenue$59,874
- Q3 2022 net loss of $4.49M ($0.18 per share) vs. $4.47M in Q3 2021.
- Cash, cash equivalents and marketable securities of $26.5M as of Sep 30, 2022.
- R&D expenses were $2.98M for Q3 2022, down from $3.15M in Q3 2021.
- FDA placed clinical hold on IkT-148009 for Parkinson's and MSA; 11 patients dosed with no serious adverse events.
- Appointed Gisele Dion to Board of Directors as Audit Committee chair.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Inhibikase Therapeutics, Inc. reported three months ended September 30, 2022 results: net income $4.49 million, EPS $0.18 per share.
- Period
- three months ended September 30, 2022
- Net income
- $4.49 million
- EPS
- $0.18 per share
- Result
- reported results
Exact text from the filing
Net loss for the three months ended September 30, 2022 was $4.49 million, or $0.18 per share
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Inhibikase Therapeutics, Inc. reported nine months ended September 30, 2022 results: net income $13.78 million, EPS $0.55 per share.
- Period
- nine months ended September 30, 2022
- Net income
- $13.78 million
- EPS
- $0.55 per share
- Result
- reported results
Exact text from the filing
Net loss for the nine months ended September 30, 2022, was $13.78 million or $0.55 per share
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.